+44 7868 792050
Dana Farber Cancer Institute Harvard Medical School, Medical Scientist, USA
Dr. Kenneth Duma is currently employed by United States of America Department of Defense. He completed his training in Medical Oncology at Harvard Medical School. He worked at Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, where he validated pancreatic cancer and glioblastoma biomarkers to predict response to immunotherapy. During his career, Dr. Duma made several original and key observations leading to seminal contributions to the understanding of pancreatic cancer and glioblastoma in regulating clonal expansion, migration, invasion, anchorage independent growth and cytoskeleton. His previous work involved innovative studies aimed at comprehensive molecular characterization of cancer with the help of patients enrolled in translational studies and clinical trials. Dr. Kenneth Duma was able to integrate this knowledge with basic and preclinical research approaches, to develop novel biomarkers for diagnosis, early detection, prognosis, and prediction of response to therapy in cancer. In his career, Dr. Kenneth Duma trained and graduated 14 doctoral students in medical oncology. He currently serves as an editorial member of several reputed journals such as Journal of Clinical Toxicology, Journal of Discoveries and Journal of Frontiers in Oncology-Cancer Epidemiology & Prevention. He is a member of American Society of Cell Biology. Dr. Kenneth Duma has co-authored over 40 research articles and his work has generated over 1500 citations.
The Cancer Immunology, Target Identification and Validation laboratory focuses on the molecular and processes governing the development of cancer. The laboratory of Dr. Kenneth Ndebele Duma takes an integrated genomics and proteomics systems approach to (a) discover and validate candidate oncogenes and tumor suppressor genes using known and novel gain-of-function and loss-of-function cell-based in vitro and in vivo assays (b) elucidate the mechanisms of biomarkers driving cancer progression (c) the discovery of novel cancer therapies directed against newly discovered and rigorously validated oncogenes.